nih

How one applies and has their proposal reviewed to gain a small share of the world's largest funding source for life science research is changing. The following highlights modifications affecting grant applications submitted to the National Institutes of Health for due dates on or after January 25, 2025, as posted on their Implementation of New Initiatives and Policies page.

The Feb.

SSTI’s new analysis of NIH data reveals the agency’s external R&D spending per award has been essentially treading water for the past 25 years in terms of real dollars—rising just 4% since FY 2000 when adjusted for inflation. This slow growth comes despite the crucial role NIH funding plays in technology-based economic development (TBED) policies across many states, particularly in the biomedical and life sciences.

House Committee on Energy and Commerce Chair Cathy McMorris Rodgers recently published Reforming the National Institutes of Health: Framework for Discussion. The blueprint calls for reducing the number of NIH institutes and centers (ICs) from 27 to 15, largely by merging some of them. The reorganization and proposed funding levels are illustrated in Figure 1.

The National Institutes of Health (NIH) announced last week that it is adopting modified criteria in its grant review process beginning on January 25, 2024. The new system will continue to focus on the scientific merit of proposals (i.e., importance, rigor, and feasibility), while de-emphasizing criteria that may introduce bias into the review.

NIH recently announced awards for five Research Evaluation and Commercialization Hubs (REACH) to accelerate the creation of small businesses and the transition of academic research discoveries into products that improve patient care and enhance health. These new REACH hubs will support innovators from diverse personal, educational, and professional backgrounds across 76 non-profit research institutions spanning 12 states.

The new hubs are:

Last month, NIH came out with a policy statement that prohibits using generative AI to analyze or critique NIH grant applications and contract proposals.

NIH just launched the funding opportunity announcement for the third cohort of its regional biomedical proof-of-concept and accelerator program, the Research Evaluation and Commercialization Hubs. On Dec.

In a recent study titled Does NIH select the right healthcare ventures through the SBIR grant program?, researchers from Rutgers University and the University of Connecticut took advantage of the 2009 American Recovery and Reinvestment Act (ARRA) to conduct a natural experiment.

Accelerators, incubators and entrepreneurial assistance programs work to ensure their startups understand their product’s market competition, customers, and supply chain. As it turns out, that’s also good advice for small research-based firms trying to move from SBIR proof-of-concept funding to securing the larger Phase II awards.